Remetinostat

Remetinostat (SHP-141) is a hydroxamic acid-based histone deacetylase (HDAC) inhibitor. Remetinostat alleviates Imiquimod (HY-B0180) -induced psoriatic dermatitis. Remetinostat can be used for study of cutaneous T-cell lymphoma[1][2].

Product Specifications

CAS Number

[946150-57-8]

Product Name Alternative

SHP-141

UNSPSC

12352005

Hazard Statement

H228, H315, H319

Target

HDAC

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Remetinostat.html

Purity

98.0

Solubility

DMSO : 150 mg/mL (ultrasonic)

Smiles

O=C(OC)C1=CC=C(OC(CCCCCCC(NO)=O)=O)C=C1

Molecular Formula

C16H21NO6

Molecular Weight

323.34

Precautions

H228, H315, H319

References & Citations

[1]Yijun Deng, et al. Process Development of the Soft Histone Deacetylate Enzyme Inhibitor SHP-141: Acylation of Methyl Paraben and Suberyl Hydroxamic Acid Formation. Org. Process Res. Dev. 2016, 20, 10, 1812-1820.|[2]Jin L, et al. Topical histone deacetylase inhibitor remetinostat improves IMQ-induced psoriatic dermatitis via suppressing dendritic cell maturation and keratinocyte differentiation and inflammation. Eur J Pharmacol. 2024 Nov 15;983:177011.